HK1203946A1 - Substituted oxadiazolyl pyridinones and oxadiazolyl pyridazinones as hif inhibitors hif - Google Patents
Substituted oxadiazolyl pyridinones and oxadiazolyl pyridazinones as hif inhibitors hifInfo
- Publication number
- HK1203946A1 HK1203946A1 HK15104466.0A HK15104466A HK1203946A1 HK 1203946 A1 HK1203946 A1 HK 1203946A1 HK 15104466 A HK15104466 A HK 15104466A HK 1203946 A1 HK1203946 A1 HK 1203946A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- hif
- oxadiazolyl
- pyridinones
- pyridazinones
- inhibitors
- Prior art date
Links
- AEICGURKQCBTGN-UHFFFAOYSA-N 3-(oxadiazol-4-yl)-1H-pyridin-2-one Chemical class O=c1[nH]cccc1-c1conn1 AEICGURKQCBTGN-UHFFFAOYSA-N 0.000 title 1
- VTHQWCBUTUMWMZ-UHFFFAOYSA-N 5-(oxadiazol-4-yl)-1H-pyridazin-6-one Chemical class O1N=NC(=C1)C=1C(NN=CC1)=O VTHQWCBUTUMWMZ-UHFFFAOYSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11185480 | 2011-10-17 | ||
PCT/EP2012/070484 WO2013057101A1 (de) | 2011-10-17 | 2012-10-16 | Substituierte oxadiazolylpyridinone und - pyridazinone als hif - hemmer |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1203946A1 true HK1203946A1 (en) | 2015-11-06 |
Family
ID=47022688
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15104466.0A HK1203946A1 (en) | 2011-10-17 | 2015-05-12 | Substituted oxadiazolyl pyridinones and oxadiazolyl pyridazinones as hif inhibitors hif |
Country Status (5)
Country | Link |
---|---|
US (1) | US20140329797A1 (xx) |
EP (1) | EP2768826A1 (xx) |
CN (1) | CN104144925A (xx) |
HK (1) | HK1203946A1 (xx) |
WO (1) | WO2013057101A1 (xx) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014031928A2 (en) * | 2012-08-24 | 2014-02-27 | Philip Jones | Heterocyclic modulators of hif activity for treatment of disease |
HUE040025T2 (hu) | 2012-08-24 | 2019-02-28 | Univ Texas | A HIF aktivitás heterociklusos modulátorai betegség kezelésére |
CN105530923B (zh) | 2013-09-09 | 2019-07-23 | 佩洛通治疗公司 | 芳基醚及其用途 |
ES2737148T3 (es) | 2013-12-16 | 2020-01-10 | Peloton Therapeutics Inc | Análogos de sulfona y sulfoximina cíclicos y usos de los mismos |
WO2015130790A2 (en) | 2014-02-25 | 2015-09-03 | Board Of Regents, University Of Texas System | Salts of heterocyclic modulators of hif activity for treatment of disease |
US9522907B2 (en) * | 2014-07-07 | 2016-12-20 | Council Of Scientific & Industrial Research | Anticancer agent and process for the preparation thereof |
WO2016145045A1 (en) | 2015-03-11 | 2016-09-15 | Peloton Therapeutics, Inc. | Compositions for use in treating glioblastoma |
EP3267792A4 (en) | 2015-03-11 | 2018-09-26 | Peloton Therapeutics, Inc. | Compositions for use in treating pulmonary arterial hypertension |
WO2016144825A1 (en) | 2015-03-11 | 2016-09-15 | Peloton Therapeutics, Inc. | Aromatic compounds and uses thereof |
EP3268362B1 (en) | 2015-03-11 | 2021-10-20 | Peloton Therapeutics, Inc. | Substituted pyridines and uses thereof |
WO2016168510A1 (en) | 2015-04-17 | 2016-10-20 | Peloton Therapeutics, Inc. | Combination therapy of a hif-2-alpha inhibitor and an immunotherapeutic agent and uses thereof |
US9796697B2 (en) | 2015-06-12 | 2017-10-24 | Peloton Therapeutics, Inc. | Tricyclic inhibitors of HIF-2-alpha and uses thereof |
PL3533787T3 (pl) | 2016-10-27 | 2021-03-08 | Fujian Cosunter Pharmaceutical Co., Ltd. | Związek pirydonowy jako inhibitor c-Met |
CN107235873B (zh) * | 2017-07-04 | 2018-11-06 | 中节能万润股份有限公司 | 一种美司钠的制备方法 |
KR102374933B1 (ko) * | 2018-04-26 | 2022-03-15 | 푸젠 코선터 파마슈티컬 컴퍼니 리미티드 | c-Met 억제제의 결정형과 이의 염 형태 및 제조 방법 |
AU2019374812A1 (en) | 2018-11-06 | 2021-06-10 | Edgewise Therapeutics, Inc. | Pyridazinone compounds and uses thereof |
WO2020097266A1 (en) | 2018-11-06 | 2020-05-14 | Edgewise Therapeutics, Inc. | Pyridazinone compounds and uses thereof |
DK3877052T3 (da) | 2018-11-06 | 2023-09-25 | Edgewise Therapeutics Inc | Pyridazinonforbindelser og anvendelser deraf |
US20230101768A1 (en) * | 2021-08-13 | 2023-03-30 | The Board Of Regents Of The University Of Texas System | Method to treat manganese toxicity and manganese-induced parkinsonism in humans |
CN116444454B (zh) * | 2023-06-16 | 2023-09-12 | 中国医学科学院医药生物技术研究所 | N-羟基脒衍生物及制备方法和应用、肿瘤免疫治疗药物 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1679313A3 (en) * | 2001-02-21 | 2006-08-16 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
CA2476012C (en) | 2002-02-14 | 2011-04-19 | Pharmacia Corporation | Substituted pyridinones as modulators of p38 map kinase |
JP4499721B2 (ja) | 2003-06-30 | 2010-07-07 | ヒフ バイオ,インク. | 化合物、組成物および方法 |
CL2004002050A1 (es) | 2003-08-13 | 2005-06-03 | Pharmacia Corp Sa Organizada B | Compuestos derivados de piridinonas sustituidas; su uso en el tratamiento de afecciones causadas o exacerbadas por actividad p38 map kinasa y/o tnf no regulada, tales como inflamaciones, tumores, sida y otros. |
US20060189661A1 (en) * | 2003-11-03 | 2006-08-24 | Wagenen Bradford V | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
DE102008020113A1 (de) * | 2008-04-23 | 2009-10-29 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Dihydropyrazolone und ihre Verwendung |
WO2007065010A2 (en) | 2005-12-02 | 2007-06-07 | Hif Bio, Inc. | Anti-angiogenesis compounds |
RU2009146851A (ru) | 2007-05-18 | 2011-06-27 | Байер Шеринг Фарма Акциенгезельшафт (DE) | Гетероарил-замещенные пиразольные производные, которые могут использоваться для лечения гиперпролиферативных нарушений и заболеваний, связанных с ангиогенезом |
WO2009148452A1 (en) * | 2008-06-06 | 2009-12-10 | Abbott Laboratories | Novel 1,2,4 oxadiazole compounds and methods of use thereof |
CA2743424A1 (en) * | 2008-11-14 | 2010-05-20 | Michael Haerter | Heteroaromatic compounds for use as hif inhibitors |
DE102008057344A1 (de) | 2008-11-14 | 2010-05-20 | Bayer Schering Pharma Aktiengesellschaft | Aminoalkyl-substituierte Aryl-Verbindungen und ihre Verwendung |
BRPI0921257A2 (pt) | 2008-11-14 | 2016-02-23 | Bayer Schering Pharma Ag | composto de arila heterociclicamente subsittuidos como inibidores hif |
WO2014031928A2 (en) * | 2012-08-24 | 2014-02-27 | Philip Jones | Heterocyclic modulators of hif activity for treatment of disease |
-
2012
- 2012-10-16 WO PCT/EP2012/070484 patent/WO2013057101A1/de active Application Filing
- 2012-10-16 EP EP12772952.3A patent/EP2768826A1/de not_active Withdrawn
- 2012-10-16 US US14/352,379 patent/US20140329797A1/en not_active Abandoned
- 2012-10-16 CN CN201280062119.0A patent/CN104144925A/zh active Pending
-
2015
- 2015-05-12 HK HK15104466.0A patent/HK1203946A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
EP2768826A1 (de) | 2014-08-27 |
CN104144925A (zh) | 2014-11-12 |
US20140329797A1 (en) | 2014-11-06 |
WO2013057101A1 (de) | 2013-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1203946A1 (en) | Substituted oxadiazolyl pyridinones and oxadiazolyl pyridazinones as hif inhibitors hif | |
HK1208862A1 (en) | Novel lactamase inhibitor and method for producing same | |
HK1209739A1 (en) | Pyridazine and pyridine derivatives as nampt inhibitors nampt | |
HK1202879A1 (en) | Compositions and methods for using csf1r inhibitors csf1r | |
EP2678018A4 (en) | COMBINATION OF CHINESE HEMMER AND USES THEREOF | |
ZA201303793B (en) | Substituted quinoline compounds and methods of use | |
HK1206743A1 (en) | 4-hydroxy-isoquinoline compounds as hif hydroxylase inhibitors hif 4-- | |
HK1198827A1 (en) | Dyrk1 inhibitors and uses thereof dyrk1 | |
HUE057264T2 (hu) | Eljárás új IDH1 inhibitorok elõállítására | |
HK1202333A1 (en) | Combination of kinase inhibitors and uses thereof | |
RS58892B1 (sr) | Jedinjenja 3-aminocikloalkila kao inhibitori ror-gama-t i njihove upotrebe | |
HRP20151310T1 (xx) | Spojevi piridazinona i njihova uporaba kao inhibitori daao | |
ZA201401653B (en) | Pyrazol-4yl-heterocyclyl-carboxamide compounds and methods of use | |
EP2710665A4 (en) | APPARATUS AND METHODS RELATING TO FERRITE CIRCULATORS | |
EP2640190A4 (en) | MODIFIED NICOTINIC COMPOUNDS AND ASSOCIATED METHODS | |
EP2635587A4 (en) | NOVEL 6-ARYLAMINOPYRIDONECARBOXAMIDES AS MEK INHIBITORS | |
EP2773358A4 (en) | COMPOSITIONS AND METHODS FOR HEMOSTASE | |
ZA201307476B (en) | New pyridazinone and pyridone compounds | |
EP2688901A4 (en) | INHIBITORS OF 17SS-HSD1, 17SS-HSD3 AND 17SS-HSD10 | |
EP2709999A4 (en) | QUINAZOLINE-7-ETHER COMPOUNDS AND METHODS OF USE | |
EP2922865A4 (en) | INHIBITORS OF THE T-CELL SPECIFIC ALTERNATIVE P38 ACTIVATING PATH AND METHOD OF USE |